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Abstract
Objective: The American Diabetes Association (ADA) recently published new clinical guidelines in which hemoglobin A1c
(HbA1c) was recommended as a diagnostic test for diabetes. The present study was to investigate the association between
HbA1c and cardiovascular risk, and compare the associations with fasting glucose and 2-hour oral glucose tolerance test
(2 h OGTT).
Research Design and Methods: The study samples are from a community-based health examination survey in central
China. Carotid-to-femoral pulse wave velocity (cfPWV) and HbA1c were measured in 5,098 men and women.
Results: After adjustment for age, sex, and BMI, the levels of HbA1c were significantly associated with an increasing trend of
cfPWV in a dose-dependent fashion (P for trend ,0.0001). The associations remained significant after further adjustment for
blood pressure, heart rate, and lipids (P=0.004), and the difference in cfPWV between the highest and the lowest quintiles
of HbA1c was 0.31 m/s. Fasting glucose and 2 h OGTT were not associated with cfPWV in the multivariate analyses. HbA1c
showed additive effects with fasting glucose or 2 h OGTT on cfPWV. In addition, age and blood pressure significantly
modified the associations between HbA1c and cfPWV (P for interactions ,0.0001 for age; and =0.019 for blood pressure).
The associations were stronger in subjects who were older ($60 y; P for trend=0.004) and had higher blood pressure
($120 [systolic blood pressure]/80 mmHg [diastolic blood pressure]; P for trend=0.028) than those who were younger and
had lower blood pressure (P for trend .0.05).
Conclusions: HbA1c was related to high cfPWV, independent of conventional cardiovascular risk factors. Senior age and
high blood pressure might amplify the adverse effects of HbA1c on cardiovascular risk.
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Introduction
Recently, the American Diabetes Association (ADA) published
new clinical guidelines in which hemoglobin A1c (HbA1c) level, in
addition to fasting glucose and 2-hour oral glucose tolerance test
(2 h OGTT), was recommended as a diagnostic test for diabetes
[1]. HbA1c is a marker of long-term glycemic exposure, reflecting
an average blood glucose level over 2–3 month period of time.
The cut-points for the diagnosis of diabetes are based on the
presence of long-term complications. However, the current
evidence for the ADA recommendation is largely from the studies
on the relations between HbA1c and microvascular diseases
especially retinopathy [2]. Even though macrovascular disease
complications are more prevalent and the primary causes for
mortality in diabetes, the data about the associations between
HbA1c and macrovascular risk are surprisingly lacking.
Arterial stiffness is an established marker for early-stage
atherosclerosis. Among various approaches to assess early-stage
arterial stiffness, carotid-to-femoral pulse wave velocity (cfPWV)
has been widely recognized a gold standard method [3], and
independently associated with cardiovascular outcomes such as
myocardial infarction, heart failure, and mortality [4–7]. Some
recent studies associated HbA1c with arterial stiffness measured by
cfPWV in patients with type 2 diabetes [8] and hemodialysis [9].
Studies examining the relation between HbA1c and arterial
stiffness in the general population are sparse. In addition, fasting
and post-challenge glucose concentrations were also related to
accelerated stiffening of the elastic arteries that contributes to the
excessive cardiovascular risk [7,10,11]. The effects of various
glucose exposures are not perfectly concordant and may be
independent [12]. However, little is known about the relative
influence of HbA1c and fasting and post-challenge glucose on
cardiovascular risk.
The aim of this study was to examine the associations between
HbA1c as the marker of long-term glucose exposure and cfPWV
PLOS ONE | www.plosone.org 1 August 2012 | Volume 7 | Issue 8 | e38485in a large sample of Chinese adults, and to compare with the
associations of fasting glucose and 2 h OGTT. We also assessed
the modification effects of age, sex, obesity and blood pressure on
the relations between glucose exposures and aortic arterial
stiffness.
Materials and Methods
Study population
In the Cardiometabolic Risk in Chinese (CRC) Study, we
performed a community-based health examination survey for
6,431 individuals (18–93 y) who were randomly selected from
residents living in the urban area of Xuzhou, China, in 2009.
Written consents were obtained from all the participants. The
study was reviewed and approved by the ethics committee of the
Central Hospital of Xuzhou, China. Among the participants,
5,514 individuals were measured for both cfPWV and HbA1c. For
the present study, we excluded subjects with history of diabetes, or
fasting glucose$7.0 mmol/L, and/or 2 h OGTT $11.1 mmol/
L, and/or HbA1c$6.5% [12,13]. In total 5,098 men and women
were included in the final analyses. There was not significant
difference in age and anthropometrics between individuals who
were included and those who were not included in the analyses.
Assessment of Carotid-to-femoral PWV
Carotid-to-femoral PWV in subjects at rest was measured using
Complior device (Artech-Medical, Pantin, France) that allows
pulse wave recording and automatic calculation of cfPWV with 2
transducers. The operator recorded in succession the right carotid
and femoral waveforms. cfPWV is calculated as the distance
between the two recording sites divided by the time delay between
the feet of the two waveforms at each site. Sixteen cfPWVs were
measured for each participant. After removing 6 extreme values (3
maximum and 3 minimum), an average value of cfPWV was
calculated.
Assessment of biomarkers and covariates
Venous blood sample was drawn from all subjects after an
overnight fast (10 h). The blood was transferred into glass tubes
and allowed to clot at room temperature. Immediately following
clotting serum was separated by centrifugation for 15 min at
3,000 rpm. HbA1c was measured using high performance liquid
chromatography (HPLC; HLC-723G7 hemoglobin HPLC ana-
lyzer, Tosoh Corp.) according to the standardized method.
Participants with no history of diabetes underwent a 75-g oral
glucose tolerance test (OGTT). Blood samples were drawn at
120 minutes after the glucose or carbohydrate load. Plasma
glucose was measured using the hexokinase glucose-6-phosphate
dehydrogenase method (Type 7600; Hitachi Ltd., Tokyo, Japan).
The levels of total cholesterol, triglyceride, high-density lipoprotein
cholesterol (HDL-C), and low-density lipoprotein cholesterol
(LDL-C) were determined enzymatically using an autoanalyzer
(Type 7600; Hitachi Ltd., Tokyo, Japan).
Height was measured to the nearest 0.5 cm without shoes and
body weight was measured to the nearest 100 grams without
shoes. Body mass index (BMI) was calculated as weight (in
kilograms) divided by height (in meters) squared. Waist circum-
ference was measured at the mid-point between the lowest rib
margin and the iliac crest. Blood pressure was measured at the
same time of cfPWV measurement after the subject had rested for
at least 5 minutes with a mercury manometer by doctors. The
subject’s arm was placed at the heart level. Three measurements,
60 seconds apart, were taken. Systolic blood pressure (SBP) was
defined as the average of the three SBP readings. Diastolic blood
pressure (DBP) was defined as the average of the three DBP
readings. The mean arterial pressure (MAP) was calculated as 2/
3(DBP) +1/3(SBP).
Statistical analyses
A linear regression model was used to evaluate associations
between glucose exposures (HbA1c, fasting glucose, and 2 h
OGTT) and cfPWV, adjusting for covariates. Glucose exposures
were analyzed in quintiles. cfPWV was analyzed as the dependent
variable, and levels of HbA1c, fasting glucose, or 2 h OGTT were
analyzed as the independent variables. Tests for linear trend were
calculated by assigning median value for each quintile of intake
and treated as continuous variables. We adjusted for the potential
confounding variables: age, sex, BMI, MAP, heart rate and lipids
(total cholesterol, triglyceride, HDL-C and LDL-C). The effect
modifications of age (,40, 40–59, $60 y), BMI (,25, $25 kg/
m
2), sex, and blood pressure (low vs high by the cutoffs
SBP$120 mmHg and DBP$80 mmHg) were tested by introduc-
tion of the cross-products of the tested variables and HbA1c into
the models. We used the SAS statistical package for all analyses
(Version 9.1, SAS Institute, Cary, NC). All P-values are two-sided.
Results
In total 5,098 men and women were included in the analyses.
Table 1 presents the characteristics of the participants by the
quintiles of HbA1c. Individuals with higher HbA1c had higher
SBP, DBP, BMI, waist circumference, fasting glucose, 2 h OGTT,
total cholesterol, triglyceride, and LDL-C, but lower HDL-C than
those who were with lower HbA1c.
We first examined the associations between three measures of
glucose exposure (HbA1c, fasting glucose and 2 h OGTT) and
cfPWV (Table 2). In the models adjusting for age, sex and BMI,
all the three measures were significantly associated with increasing
trend of cfPWV (P,0.0001). When MAP was further adjusted, the
associations for fasting glucose (P=0.01), 2 h OGTT (P=0.04),
and HbA1c (P=0.005) remained significant. When other covar-
iates including heart rate, total cholesterol, TG, HDL-C and LDL-
C were further adjusted, the associations for fasting glucose and
2 h OGTT were attenuated to be not significant, while the
association for HbA1c remained significant (P=0.004). In the
fully-adjusted model, the difference in cfPWV between the highest
and the lowest quintiles of HbA1c was 0.31 m/s.
According to the ADA recommendation [12], we defined
‘prediabetes’ by the cutoffs of the three glucose exposures, i.e.
impaired fasting glucose (IFG, fasting glucose 5.6–6.9 mmol/L),
impaired glucose tolerance (IGT, 2 h OGTT 7.8–11.0 mmol/L),
and high HbA1c (5.7–6.4%) to represent an increased risk of
diabetes but without fulfilling the criteria of diagnosis. The
prevalence of IFG, IGT, and high HbA1c in this non-diabetic
population were 12%, 14.3%, and 14.8%; respectively. The
differences in cfPWV between individuals with IFG, IGT and high
HbA1c and those without these abnormalities were 0.97, 1.08 and
0.92 m/s (P,0.0001; Figure 1).
We then examined the additive effects of HbA1c with fasting
glucose and 2 h OGTT on cfPWV (Figure 2). In the analyses
adjusting for age, sex, and BMI, as compared with individuals with
fasting glucose ,5.6 mmol/L and HbA1c ,5.7%, those with high
HbA1c only, with IFG only, and with both IFG and high HbA1c
had 0.28 (P=0.03), 0.27 (P=0.015) and 0.48 m/s (P=0.0003)
higher cfPWV. Similarly, as compared individuals with 2 h
OGTT ,7.8 mmol/L and HbA1c ,5.7%, those with high
HbA1c only, with IGT only, and with both IGT and high HbA1c
had 0.18 (P=0.10), 0.28 (P=0.008) and 0.44 m/s (P=0.0001)
Hemoglobin A1c and Aortic Arterial Stiffness
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materially change the results. Our data also indicate that
individuals of both high HbA1c and IFG or IGT had significantly
higher levels of cfPWV compared with those who only had high
HbA1c (p=0.036 and 0.03; respectively; or those only had IFG
(p=0.02); or those only had IGT (p=0.04).
Pulse wave velocity is strongly associated with age and blood
pressure, and is also related to sex and BMI [14–16]. Therefore,
we examined whether these variables modified the relation
between HbA1c and cfPWV. We found significant interactions
between HbA1c and age (,40, 40–59, $60 y; P,0.0001) and
blood pressure (low vs high by the cutoffs SBP$120 mmHg and/
Table 1. Clinical characteristics of the participants by HbA1c levels.
HbA1c in quintiles P value
Variables Q1 Q2 Q3 Q4 Q5
,5.06 5.06–5.15 5.16–5.33 5.34–5.52 5.53–6.49
N of participants 1,181 1,043 1,068 772 1,034
Age, years 43610 46612 49612 52613 56613 ,0.0001
Systolic blood pressure, mmHg 122616 123616 125616 128616 133618 ,0.0001
Diastolic blood pressure, mmHg 78611 78611 79611 81611 82612 ,0.0001
Heart rate, bpm 71697 0 611 70610 70610 70611 0.35
Waist circumference, cm 82.669.7 83.769.9 86.169.4 87.669.4 90.769.1 ,0.0001
Body mass index, kg/m
2 23.663.0 24.063.1 24.662.9 25.263.0 26.263.2 ,0.0001
$25 kg/m
2 29.7% 34% 41.5% 52.6% 60.3% ,0.0001
Men, % 55% 56.1% 59.7% 56.6% 54.3% 0.1
Biochemical measures
Glucose, mmol/L 4.7960.41 4.8860.38 4.9960.45 5.0760.44 5.4360.62 ,0.0001
2h OGTT, mmol/L 5.5761.19 5.7661.22 6.0061.26 6.4261.39 7.3161.71 ,0.0001
Total cholesterol, mmol/L 4.7560.83 4.8960.81 5.1160.90 5.1760.96 5.3360.94 ,0.0001
Triglyceride, mmol/L 1.3361.22 1.3761.03 1.5961.58 1.6961.50 1.8861.78 ,0.0001
HDL-C, mmol/L 1.2960.31 1.2660.30 1.2560.30 1.2160.29 1.1960.28 ,0.0001
LDL-C, mmol/L 2.7460.7 2.9460.69 3.0860.81 3.1660.75 3.2660.81 ,0.0001
Abbreviations: HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol;
OGTT, oral glucose tolerance test; bpm, beats per minute.
Data are mean 6 standard deviations for the continuous variables and percentage for the categorical variables.
Linear regression model was used to test trend for continuous variables; x
2 test was used for the categorical variables.
doi:10.1371/journal.pone.0038485.t001
Table 2. Associations of fasting glucose, 2h OGTT, and HbA1c with cfPWV (m/s).
Glucose exposures in quintiles
P
for trend
Models Q1 Q2 Q3 Q4 Q5
Fasting glucose
Age, sex, and BMI adjusted 10.49 (0.05) 10.65 (0.05) 10.57 (0.05) 10.69 (0.05) 11.02 (0.05) ,0.0001
Further adjusted for blood pressure 10.62 (0.05) 10.71 (0.05) 10.58 (0.05) 10.64 (0.05) 10.86 (0.05) 0.01
Further adjusted for other covariates* 10.57 (0.06) 10.56 (0.06) 10.45 (0.06) 10.48 (0.06) 10.69 (0.06) 0.44
2h OGTT
Age, sex, and BMI adjusted 10.62 (0.06) 10.57 (0.06) 10.58 (0.06) 10.68 (0.06) 11.04 (0.06) ,0.0001
Further adjusted for blood pressure 10.70 (0.05) 10.60 (0.06) 10.64 (0.05) 10.66 (0.05) 10.87 (0.06) 0.04
Further adjusted for other covariates* 10.56 (0.06) 10.56 (0.06) 10.44 (0.06) 10.52 (0.07) 10.69 (0.08) 0.56
HbA1c
Age, sex, and BMI adjusted 10.59 (0.05) 10.63 (0.05) 10.56 (0.05) 10.69 (0.06) 10.95 (0.05) ,0.0001
Further adjusted for blood pressure 10.60 (0.05) 10.68 (0.05) 10.60 (0.05) 10.67 (0.06) 10.84 (0.05) 0.005
Further adjusted for other covariates* 10.46 (0.05) 10.55 (0.06) 10.47 (0.06) 10.61 (0.07) 10.77 (0.07) 0.004
*: Other covariates include heart rate, total cholesterol, triglyceride, HDL-C, and LDL-C.
cfPWV is presented as mean (standard error).
doi:10.1371/journal.pone.0038485.t002
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HbA1c were stronger in participants with age $60 y (P for
trend=0.004) than in those who were younger (P for trend .0.05)
(Table 3); and were stronger in participants with high MAP (P for
trend=0.028) than those with low MAP (P for trend .0.05)
(Figure 3). Although the associations between HbA1c and cfPWV
appeared to be more significant in women and in subjects with
BMI ,25 kg/m
2 than in men and in those with BMI $25 kg/m
2,
the tests for interactions with sex and BMI were not significant
(Table 3).
Discussion
In this study of a large sample of Chinese adults, long-term
glycemic exposure, measured by HbA1c, was significantly
associated with higher cfPWV, independent of other cardiovascu-
lar risk factors. We found that fasting glucose and 2 h OGTT
showed additive effects with HbA1c on cfPWV. In addition, age
and blood pressure significantly modified the associations between
HbA1c and cfPWV.
Carotid-femoral pulse wave velocity, a gold-standard measure
of intrinsic stiffness of the aortic wall, is an important predictor of
cardiovascular disease risk [4,18,19]. Our findings are consistent
with some previous studies. Matsumae et al. reported that HbA1c
level was an independent determinant of cfPWV in hemodialysis
patients with and without diabetes [9]. The association between
HbA1c levels and increased arterial stiffness (measured by
brachial-ankle pulse wave velocity [baPWV]) was recently
observed in patients with type 2 diabetes [8]. Our data indicate
that the long-term glucose exposure HbA1c may lead to increased
arterial stiffness in non-diabetic individuals. The precise mecha-
nisms how chronic glucose exposure may affect arterial stiffening
are not fully understood. It was documented that BMI, blood
pressure, heart rate, total cholesterol, LDL-C, HDL-C and
triglyceride were related to cfPWV [15,16,20,21]. In our study,
adjustment for these potential risk factors did not change the
associations of HbA1c with cfPWV, suggesting that the effects of
HbA1c are not mediated by these metabolic changes and likely to
be through other independent pathways.
Individuals with prediabetes defined by the three measures of
glucose exposure HbA1c, fasting glucose and 2 h OGTT all had
significantly higher cfPWV. Our data indicate that, however, the
changes in arterial stiffness were better associated with long-term
glycemic exposure HbA1c than single measures of fasting glucose
and 2 h OGTT on the continuous scales. Though highly
correlated, these various measures for glucose exposure may
convey different information regarding their relations with
cardiovascular risk. Our data are consistent with previous studies
in which HbA1c was a better predictor of cardiovascular disease
than fasting glucose [22] and post-challenge glucose levels [23]. In
addition, HbA1c has shown more consistent associations with
retinopathy than fasting glucose level [2]. HbA1c value is a more
stable biological index for long-term glycemia exposure than
fasting glucose, which fluctuate within and between days and is
therefore not a clear indicator of general glycemia.
Various mechanisms have been proposed to link glucose
exposure with development of atherosclerosis. Long-term high
Figure 1. Geometric means of carotid-to-femoral pulse wave
velocity (cfPWV, in m/s) by the presence of prediabetes status
defined by IFG, IGT, and high HbA1c (5.7–6.4%). The analyses
were adjusted for age, sex, BMI, MAP, heart rate and lipids (total
cholesterol, triglyceride, HDL-C and LDL-C). Symbol ‘*’ represents
significant difference (p,0.05) between the ‘absence’ and ‘presence’
groups of each marker.
doi:10.1371/journal.pone.0038485.g001
Figure 2. Geometric means of cfPWV (in m/s) by the
combinations of high HbA1c (5.7–6.4%) with IFG and IGT.
Symbol ‘+’ represents the presence of the corresponding glucose
exposures. The analyses were adjusted for age, sex, BMI, MAP, heart rate
and lipids (total cholesterol, triglyceride, HDL-C and LDL-C). ‘*’
represents significant difference (p,0.05) comparing individuals with
high HbA1c and IFG/IGT with the normal subjects (without any of these
abnormalities); ‘**’ represents significant difference (p,0.05) comparing
individuals with high HbA1c and IFG/IGT with those who had only high
HbA1c; and ‘***’ represents significant difference (p,0.05) comparing
individuals with high HbA1c and IFG/IGT with those who had only IFG
or IGT.
doi:10.1371/journal.pone.0038485.g002
Figure 3. The geometric means of cfPWV (in m/s) by according
to HbA1c (in quintiles) by the presence/absence of high blood
pressure defined by SBP $120 mmHg and DBP $80 mmHg.
The analyses were adjusted for age, sex, BMI, heart rate and lipids.
doi:10.1371/journal.pone.0038485.g003
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glycation endproducts (AGE), which result from non-enzymatic
protein glycation forming irreversible cross-links in stable tissue
proteins [24]. Matrix in the blood vessel wall is steadily reduced
from exposure to AGE [25]. In addition, high AGE is known to
impact endothelial function by quenching NO, enhancing the
generation of reactive oxygen species (ROS), and induction of
inflammation. All these alterations may contribute to development
and progression of atherosclerosis [24,26]. It has been acknowl-
edged that various glucose exposures are not perfectly concordant
regarding their relations with disease outcomes [12]. Our study
suggests that different measures of glucose exposure might have
additive effects on arterial stiffness. Although these measures have
been individually related to cardiovascular risk [8,10], the
mechanisms underlying their joint effects are not unequivocally
clarified. These various measures may reflect distinct abnormal-
ities in glucose metabolism. High fasting glucose detects fasting
hyperglycaemia, which is more typical of pancreatic b cell
dysfunction; whereas high 2 h OGTT reveals post-prandial
hyperglycaemia that is more closely associated with insulin
resistance [27].http://pmj.bmj.com.ezp-prod1.hul.harvard.edu/
content/86/1021/656.long – ref-11 HbA1c provides a weighted
average of blood glucose for the lifespan of an erythrocyte and the
measure may reflect recent changes in diet or treatment [28]. We
postulate that at least parts of the pathways linking these different
markers to cardiovascular conditions are not overlapped. There-
fore, when different markers are considered jointly, their effects
would appear additive. Our findings of the additive effects of
different measures of glucose exposures highlight the importance
to measure long-term glucose exposure in addition to fasting
glucose and 2 h OGTT in characterizing individuals at high risk
of diabetes and cardiovascular complications.
Arterial stiffness is strongly associated with age and blood
pressure [21]. The data from the present study showed that these
two factors significantly modified the associations between HbA1c
and cfPWV, and stronger associations were observed in the
individuals who were older and had higher blood pressure. A
synergistic effect between raised blood pressure and raise plasma
glucose on arterial stiffening was reported in middle-aged Japanese
men [29]. Though the mechanisms underlying such an additive
effect remain not clear, some studies have shown that the
coexistence of hyperglycemia and high blood pressure might
augment the production of advanced glycation end products and
deteriorate endothelial dysfunction [29,30]. Future studies are
needed to investigate the mechanisms underlying the additive
effects between HbA1c and blood pressure and aging.
The sample size of this study is large, which ensures sufficient
power to detect the moderate effects of glucose exposures on
arterial stiffness and interactions between HbA1c and other risk
factors. Our study is cross-sectional in design. Therefore, a causal
relation between HbA1c and arterial stiffness could not be derived.
In addition, the study was performed in a Chinese population.
Further studies in other populations of different ethnicities are
warranted to verify our findings. Moreover, we used the
standardized method in measurement of HbA1c. However, it
has been argued that the use of HbA1c for diagnosing diabetes has
some limitations [31]. For example, the measurement of HbA1c
level might be influenced by various medical conditions, such as
kidney failure, chronic excessive alcohol intake, acute or chronic
blood loss and liver failure. Although we have carefully excluded
patients with chronic diseases from the analysis, it is still possible
some conditions that were not assessed in our study might
influence the associations.
In summary, in the present study of non-diabetic Chinese
adults, the marker of long-term glucose exposure HbA1c showed
stronger association with aortic arterial stiffness than fasting
glucose and 2 h OGTT. Various measures for glucose exposures
might additively affect arterial stiffness. In addition, we found that
senior age and high blood pressure might amplify the effects of
chronic glucose exposure on the cardiovascular risk.
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Table 3. Stratified associations between HbA1c and cfPWV (m/s) by sex, age and BMI.
HbA1c in quintiles
Pf o r
trend
Pf o r
interaction
Q1 Q2 Q3 Q4 Q5
Age
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